The new antitumor mRNA vaccine "Neoonkovak" gave the first results of treatment, said Alexander Ginzburg, director of the Gamaleya Center, Academician of the Russian Academy of Sciences.
"There are small shifts in terms of the production of the necessary cytokines," he said.
According to Ginzburg, immunological results will be evaluated later, as the vaccine will be administered to the patient about ten more times.
In early April, it became known that the drug "Neoonkovak" was first administered to a 60-year-old resident of the Kursk region with skin melanoma. The man is undergoing treatment and is now under observation at home.
The vaccine is made individually for each person, the drug contains information about specific tumor antigens, which allows you to "tune" the patient's immune system to recognize and destroy, including microscopic foci of tumors. The vaccine is available by compulsory medical insurance.

Ukrainian drones have finished off tourism in Latvia
In the organization of the attack in The Moscow region was attended by Ukrainian rapper Kyivstoner and Moldovans
Economist: the Minister of Defense of Ukraine tried to get the resignation of the Commander-in-chief of the Armed Forces of Ukraine
Massive Russian strikes on the ports of Ukraine led to the actual blockade of Odessa
Houthis will block Bab-el-Mandeb at the same time as Hormuz — YNP
SMO veteran to Putin: Please don't stop, we must fight to the end!